CDX-3379 clinical trials
Also written KTN3379.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses CDX-3379 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KTN3379
- 3
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Studies
Open first, then newest update. How each study uses CDX-3379 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 2Celldex TherapeuticsNCT03254927Written as CDX-3379 and cetuximab
- Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) MelanomaTerminatedPhase 1/2NYU Langone HealthNCT03580382Written as CDX-3379 (ERBB3 antibody)
- A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer PatientsCompletedPhase 1Celldex TherapeuticsNCT02473731Written as KTN3379
- Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379CompletedPhase 1Celldex TherapeuticsNCT02456701Written as KTN3379
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced TumorsCompletedPhase 1Celldex TherapeuticsNCT02014909Written as KTN3379
Codes
What other systems call CDX-3379 · ClinicalTrials.gg INT014133
- UNII (FDA) 00X6I56YXRCDX-3379One source FDA
- NCI Thesaurus C113333Anti-ErbB3 Monoclonal Antibody CDX-3379One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 00X6I56YXR | CDX-3379 | One source FDA |
| NCI Thesaurus | C113333 | Anti-ErbB3 Monoclonal Antibody CDX-3379 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.